Respiratory syncytial virus (RSV)

RS viruses cause colds, flu-like illnesses and bronchiolitis mainly in the winter half-year. They often lead to hospitalisation. For newborns and infants, two long-acting monoclonal antibodies are available. In addition, three vaccines are currently available for people aged 18 and over. One of these is also approved as a vaccination for pregnant women to protect their newborns.

Information on the coverage of the costs of monoclonal antibodies and RSV vaccines by compulsory health insurance will be found (in German, French and Italian) on the FOPH webpage: Kostenübernahme bei Impfungen.

Further information

• Documents

  • Factsheet by the Federal Vaccination Commission: Routine immunisation against RSV with protective antibodies

    PDF1.15 MB10 September 2024

  • Consensus statement - recommendation on the prevention of respiratory syncytial virus (RSV) infections with the monoclonal antibody Nirsevimab (Beyfortus®) (Sep 2024)

    PDF519.85 kB10 September 2024

  • Poster - Protect your baby with RSV prophylaxis

    PDF852.33 kB11 October 2024

  • Poster – Protect your baby from RSV, via your maternal vaccination

    PDF59.16 kB6 November 2025

  Recommendations for RSV vaccination and other documents are available in German and French.

• Links

  RSV: adults (in German or French)

  RSV: pregnancy and children (in German or French)